Edward B. Garon, MD, MS
Raffaele Califano, MD
Egbert F. Smit, MD, PhD
Release Date: 6 April 2016
Given the expanding treatment landscape for advanced NSCLC, it’s an exciting time for oncologists to be able to individualise therapy in the front-line setting, as well as after progression. Anti-angiogenic therapies have a key role in treatment strategies for advanced NSCLC.
This site was created to provide clinicians with:
Information on the role of anti-angiogenic therapy in the management of patients with advanced NSCLC
Up-to-date evidence and data on anti-angiogenic therapies and other therapeutic options for patients with progressive disease